Hospital
Mercy Health-St Ritas Medical Center LLC
Mercy Health-St Ritas Medical Center LLC was paid $48.02M by Medicaid between Jan 2018 and Dec 2024, across 394 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 21% of everything it billed.
33Billing provider infoMERCY HEALTH-ST RITAS MEDICAL CENTER LLC
LIMA, OH 45801
LIMA, OH 45801
33aNPI1811939887assigned 06/12/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$48.02M
24GClaims1,337,990
24DCodes billed394
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#21 of 101
Median peer was paid$22.32M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 120,388 | $3.31M | |
| 2019 | 113,511 | $3.36M | |
| 2020 | 98,026 | $3.99M | |
| 2021 | 116,468 | $5.10M | |
| 2022 | 128,284 | $5.31M | |
| 2023 | 466,567 | $17.26M | |
| 2024incomplete | 294,746 | $9.69M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 21% | 97,815 | 84,560 | $10.25M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 56,130 | 50,838 | $6.13M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 45,726 | 38,686 | $5.16M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.8% | 27,003 | 21,761 | $3.26M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.5% | 19,279 | 18,297 | $2.15M |
| 41899 | Unlisted procedure, dentoalveolar structures | 3.8% | 1,594 | 1,120 | $1.83M |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.7% | 5,934 | 3,308 | $1.79M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.8% | 5,469 | 3,993 | $1.34M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 5,196 | 4,163 | $1.16M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 16,345 | 4,129 | $996K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.6% | 3,196 | 1,510 | $792K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 6,065 | 3,486 | $706K |
382 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 3,250 | $589K |
| G0378 | Hospital observation service, per hour | 1.1% | 8,460 | $523K |
| 64635 | 1.1% | 1,212 | $511K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 7,175 | $471K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 7,545 | $442K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 815 | $429K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,824 | $424K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,542 | $411K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,384 | $400K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,973 | $371K |
| 80053 | Comprehensive metabolic panel | <1% | 52,048 | $356K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,427 | $350K |
| 64493 | <1% | 534 | $266K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,488 | $251K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 13,484 | $219K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,073 | $186K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,089 | $172K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 26,986 | $152K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,097 | $151K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 750 | $150K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,184 | $141K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 413 | $132K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 15,530 | $132K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 447 | $129K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,638 | $127K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,940 | $127K |
| 95811 | <1% | 227 | $126K | |
| 93017 | <1% | 1,831 | $122K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,406 | $116K |
| 70496 | <1% | 544 | $111K | |
| 76770 | <1% | 709 | $109K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,278 | $104K |
| 76642 | <1% | 855 | $103K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 10,023 | $101K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 89,823 | $92K |
| 94726 | <1% | 850 | $91K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 948 | $87K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,732 | $86K |
| 70491 | <1% | 343 | $85K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 15,200 | $78K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,502 | $73K |
| 84484 | <1% | 25,975 | $70K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 39,280 | $69K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 481 | $68K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,779 | $65K |
| 36415 | Collection of venous blood by venipuncture | <1% | 98,655 | $61K |
| 93971 | <1% | 873 | $61K | |
| 76536 | <1% | 614 | $61K | |
| 71250 | <1% | 686 | $59K | |
| 93325 | <1% | 597 | $57K | |
| 97113 | <1% | 800 | $56K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 426 | $56K |
| 93975 | <1% | 424 | $56K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,440 | $55K |
| 97162 | <1% | 1,357 | $55K | |
| 12001 | <1% | 350 | $53K | |
| 62323 | <1% | 152 | $53K | |
| 71271 | <1% | 397 | $52K | |
| 94060 | <1% | 849 | $50K | |
| 97161 | <1% | 821 | $48K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 778 | $48K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 575 | $46K |
| 70486 | <1% | 709 | $45K | |
| 96367 | <1% | 1,240 | $45K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 34,439 | $44K |
| 94729 | <1% | 874 | $43K | |
| 97166 | <1% | 687 | $41K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,661 | $40K |
| 74018 | <1% | 1,635 | $39K | |
| 86900 | <1% | 2,053 | $37K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,020 | $37K |
| 92557 | <1% | 541 | $36K | |
| 97035 | <1% | 1,003 | $36K | |
| 80061 | Lipid panel | <1% | 2,961 | $35K |
| 72100 | <1% | 1,375 | $34K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 356 | $33K |
| 86140 | <1% | 3,615 | $33K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 104 | $33K |
| 76830 | Ultrasound, transvaginal | <1% | 706 | $32K |
| 93226 | <1% | 383 | $31K | |
| 72131 | <1% | 370 | $30K | |
| 97165 | <1% | 494 | $29K | |
| J3490 | Unclassified drugs | <1% | 351 | $28K |
| 80047 | <1% | 5,681 | $27K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,218 | $27K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,730 | $27K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 228 | $27K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,787 | $27K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,184 | $26K |
| 93970 | <1% | 207 | $26K | |
| 87070 | <1% | 14,095 | $25K | |
| 70498 | <1% | 589 | $25K | |
| 64490 | <1% | 42 | $24K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,542 | $24K |
| 87507 | <1% | 233 | $24K | |
| 80320 | <1% | 1,801 | $24K | |
| 86850 | <1% | 1,949 | $22K | |
| 85027 | <1% | 5,027 | $20K | |
| 73030 | <1% | 1,328 | $20K | |
| 73630 | <1% | 1,799 | $20K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 17,743 | $19K |
| 80076 | <1% | 7,222 | $19K | |
| 97116 | <1% | 997 | $18K | |
| 84439 | <1% | 2,210 | $18K | |
| 72040 | <1% | 538 | $17K | |
| 92523 | <1% | 264 | $17K | |
| 72141 | <1% | 140 | $17K | |
| 93458 | <1% | 13 | $17K | |
| 82728 | <1% | 1,916 | $16K | |
| 73130 | <1% | 1,472 | $16K | |
| 93225 | <1% | 390 | $16K | |
| 77065 | Tomosynthesis, mammo | <1% | 600 | $16K |
| 76870 | <1% | 165 | $16K | |
| 73502 | <1% | 890 | $15K | |
| 82607 | <1% | 1,513 | $15K | |
| 86803 | <1% | 621 | $15K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 27,272 | $15K |
| 81001 | <1% | 25,508 | $14K | |
| 90715 | <1% | 947 | $14K | |
| 83880 | <1% | 7,081 | $14K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,249 | $14K |
| 73564 | <1% | 1,392 | $14K | |
| 84702 | <1% | 1,495 | $13K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 62 | $12K |
| 83735 | <1% | 14,141 | $12K | |
| 93270 | <1% | 245 | $12K | |
| 83970 | <1% | 392 | $12K | |
| 77336 | <1% | 70 | $12K | |
| 99152 | <1% | 1,626 | $12K | |
| 73610 | <1% | 1,568 | $11K | |
| 81003 | <1% | 10,197 | $11K | |
| 73110 | <1% | 910 | $11K | |
| 92567 | <1% | 950 | $11K | |
| 73562 | <1% | 246 | $11K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 9,598 | $11K |
| 52000 | <1% | 31 | $11K | |
| 96415 | <1% | 67 | $10K | |
| 88307 | <1% | 101 | $10K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 110 | $10K |
| 72072 | <1% | 324 | $10K | |
| 82248 | <1% | 15,360 | $10K | |
| 87641 | <1% | 499 | $9K | |
| 83540 | <1% | 1,906 | $9K | |
| 83550 | <1% | 1,798 | $9K | |
| 95819 | <1% | 76 | $8K | |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 122 | $8K |
| 83690 | <1% | 21,168 | $8K | |
| 82746 | <1% | 1,349 | $8K | |
| 92558 | <1% | 125 | $8K | |
| 93660 | <1% | 90 | $8K | |
| 85651 | <1% | 2,677 | $8K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 548 | $8K |
| 82948 | <1% | 7,898 | $8K | |
| 86592 | <1% | 542 | $8K | |
| 82077 | <1% | 4,893 | $7K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,249 | $7K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 15,543 | $7K |
| 77066 | Tomosynthesis, mammo | <1% | 268 | $7K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 538 | $7K |
| 12011 | <1% | 52 | $7K | |
| 83605 | <1% | 3,949 | $7K | |
| 84703 | <1% | 11,284 | $7K | |
| 82565 | <1% | 1,518 | $6K | |
| 87340 | <1% | 425 | $6K | |
| 96376 | <1% | 2,816 | $6K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 935 | $5K |
| 85610 | <1% | 5,786 | $5K | |
| 84156 | <1% | 612 | $5K | |
| 92579 | <1% | 62 | $5K | |
| 84153 | <1% | 329 | $5K | |
| 87807 | <1% | 2,586 | $5K | |
| 20610 | <1% | 57 | $5K | |
| 86901 | <1% | 2,049 | $5K | |
| 87077 | <1% | 2,887 | $5K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 17 | $4K |
| 73080 | <1% | 472 | $4K | |
| 87205 | <1% | 2,793 | $4K | |
| 86038 | <1% | 270 | $4K | |
| 97597 | <1% | 169 | $4K | |
| 87522 | Neg quan hep c or qual rna | <1% | 102 | $4K |
| 87420 | <1% | 151 | $4K | |
| 87186 | <1% | 2,327 | $4K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 413 | $4K |
| C1769 | Guide wire | <1% | 876 | $4K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 190 | $3K |
| V5266 | Battery for use in hearing device | <1% | 491 | $3K |
| 71101 | <1% | 515 | $3K | |
| 85730 | <1% | 2,499 | $3K | |
| 74174 | <1% | 13 | $3K | |
| 77080 | <1% | 50 | $3K | |
| 94010 | <1% | 97 | $3K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 39 | $3K |
| 84425 | <1% | 233 | $3K | |
| 73140 | <1% | 349 | $3K | |
| 12002 | <1% | 15 | $3K | |
| 82043 | <1% | 457 | $3K | |
| 74183 | <1% | 15 | $3K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 707 | $3K |
| 64495 | <1% | 150 | $3K | |
| 93880 | <1% | 46 | $3K | |
| 36591 | <1% | 1,493 | $3K | |
| 97163 | <1% | 56 | $3K | |
| 92610 | <1% | 61 | $3K | |
| 73590 | <1% | 345 | $3K | |
| 82570 | <1% | 673 | $3K | |
| 85014 | <1% | 710 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,025 | $2K |
| 87040 | <1% | 2,812 | $2K | |
| 86762 | <1% | 95 | $2K | |
| A9609 | Fludeoxyglucose f18 up to 15 millicuries | <1% | 13 | $2K |
| 10060 | <1% | 13 | $2K | |
| 95816 | <1% | 17 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 15 | $2K |
| 85018 | <1% | 822 | $2K | |
| J0571 | Buprenorphine, oral, 1 mg | <1% | 517 | $2K |
| 86430 | <1% | 140 | $2K | |
| 80143 | <1% | 1,781 | $2K | |
| 84146 | <1% | 278 | $2K | |
| 83516 | <1% | 67 | $2K | |
| 81025 | <1% | 3,139 | $2K | |
| 84403 | <1% | 101 | $2K | |
| 87640 | <1% | 80 | $2K | |
| 64636 | <1% | 1,184 | $2K | |
| 84134 | <1% | 124 | $2K | |
| 82947 | <1% | 419 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,899 | $2K |
| 84550 | <1% | 364 | $2K | |
| 84100 | <1% | 994 | $2K | |
| 93242 | <1% | 45 | $2K | |
| 84520 | <1% | 825 | $2K | |
| 73090 | <1% | 474 | $2K | |
| 80329 | <1% | 239 | $1K | |
| 82330 | <1% | 566 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,736 | $1K |
| 73560 | <1% | 44 | $1K | |
| 86308 | <1% | 286 | $1K | |
| 72170 | <1% | 264 | $1K | |
| 85379 | <1% | 1,622 | $1K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,593 | $1K |
| 82784 | <1% | 154 | $1K | |
| 86706 | <1% | 53 | $1K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 415 | $1K |
| 82140 | <1% | 393 | $1K | |
| 87808 | <1% | 738 | $1K | |
| 82803 | <1% | 874 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 19,069 | $1K |
| 80179 | <1% | 1,770 | $1K | |
| 84145 | <1% | 1,520 | $974.95 | |
| 82550 | <1% | 878 | $965.69 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 48 | $916.44 |
| 84132 | <1% | 577 | $890.81 | |
| 76775 | <1% | 13 | $862.07 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 181 | $857.65 |
| 93246 | <1% | 12 | $852.55 | |
| 80051 | <1% | 182 | $824.43 | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 1,907 | $812.27 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 16 | $791.73 |
| 99153 | Mod sedat endo service >5yrs | <1% | 219 | $773.71 |
| 87210 | <1% | 767 | $772.24 | |
| 87147 | <1% | 679 | $743.28 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 119 | $686.28 |
| 82374 | <1% | 472 | $681.57 | |
| 83615 | <1% | 336 | $627.52 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,259 | $593.65 |
| 87220 | <1% | 608 | $537.96 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,468 | $511.07 |
| 82272 | <1% | 317 | $505.63 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,773 | $467.77 |
| 69209 | <1% | 15 | $461.94 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,361 | $459.61 |
| 84460 | <1% | 66 | $451.84 | |
| 00731 | <1% | 504 | $401.92 | |
| 01936 | <1% | 1,675 | $399.24 | |
| 76376 | <1% | 473 | $392.48 | |
| J2704 | Injection, propofol, 10 mg | <1% | 12,104 | $371.90 |
| 84450 | <1% | 51 | $344.04 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 10,831 | $335.85 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,566 | $323.81 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 965 | $322.92 |
| 80305 | <1% | 208 | $315.97 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 602 | $313.12 |
| 85046 | <1% | 272 | $274.72 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 2,217 | $265.78 |
| 82533 | <1% | 58 | $265.71 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,211 | $263.60 |
| 01992 | <1% | 1,373 | $258.93 | |
| 73552 | <1% | 39 | $252.62 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 187 | $238.69 |
| 83525 | <1% | 12 | $238.25 | |
| 51798 | <1% | 51 | $230.68 | |
| 73060 | <1% | 73 | $227.30 | |
| 80164 | <1% | 33 | $226.37 | |
| 70360 | <1% | 27 | $223.75 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 788 | $218.53 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,187 | $218.36 |
| 87075 | <1% | 497 | $217.50 | |
| 88304 | <1% | 554 | $216.19 | |
| 36600 | <1% | 36 | $216.12 | |
| 82150 | <1% | 25 | $208.06 | |
| 51701 | <1% | 15 | $195.99 | |
| 82010 | <1% | 580 | $176.45 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,075 | $174.78 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 587 | $173.55 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 12,915 | $169.88 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,819 | $169.71 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,560 | $169.36 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,085 | $151.26 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 425 | $146.26 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,423 | $143.36 |
| 36416 | <1% | 1,507 | $135.05 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 291 | $132.18 |
| 29125 | <1% | 111 | $124.39 | |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 544 | $116.33 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 92 | $106.21 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,265 | $104.49 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 216 | $99.44 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,152 | $97.30 |
| 83883 | <1% | 19 | $93.22 | |
| 82950 | <1% | 13 | $89.16 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 409 | $76.41 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 838 | $76.39 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,193 | $74.55 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 1,456 | $66.80 |
| 84295 | <1% | 25 | $66.63 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,106 | $66.06 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,581 | $65.07 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 188 | $46.13 |
| 72158 | <1% | 16 | $45.75 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 98 | $44.16 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 29 | $43.52 |
| 80074 | <1% | 16 | $42.53 | |
| 88342 | <1% | 137 | $40.23 | |
| 85520 | <1% | 82 | $39.05 | |
| 80177 | <1% | 28 | $35.78 | |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | <1% | 123 | $34.82 |
| 80365 | <1% | 25 | $19.30 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 439 | $19.10 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 141 | $12.20 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 73 | $11.67 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 79 | $11.53 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,899 | $11.04 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 235 | $10.41 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 168 | $9.98 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 28 | $9.63 |
| 82435 | <1% | 21 | $9.47 | |
| 84155 | <1% | 16 | $9.19 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 221 | $3.34 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 20 | $2.57 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 54 | $1.30 |
| 64494 | <1% | 464 | $1.15 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 34 | $0.69 |
| 84165 | 0% | 14 | $0.00 | |
| 01940 | 0% | 127 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 74 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 228 | $0.00 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 59 | $0.00 |
| A4641 | Radiopharmaceutical, diagnostic, not otherwise classified | 0% | 25 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 15 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 14 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 14 | $0.00 |
| 00840 | 0% | 206 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 18 | $0.00 |
| 76942 | 0% | 13 | $0.00 | |
| 64491 | 0% | 40 | $0.00 | |
| 94669 | 0% | 26 | $0.00 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 53 | $0.00 |
| 94761 | 0% | 1,438 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 1,084 | $0.00 |
| 93320 | 0% | 522 | $0.00 | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 20 | $0.00 |
| G0379 | Direct admission of patient for hospital observation care | 0% | 26 | $0.00 |
| 94760 | 0% | 177 | $0.00 | |
| 96368 | 0% | 370 | $0.00 | |
| C9399 | Unclassified drugs or biologicals | 0% | 107 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 40 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 21 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 28 | $0.00 |
| J2305 | Injection, nitroglycerin, 5 mg | 0% | 40 | $0.00 |
| 64492 | 0% | 14 | $0.00 | |
| 84300 | 0% | 16 | $0.00 | |
| 00813 | 0% | 18 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRIEGER, TIM (PRESIDENT)